Polymyalgia rheumatica and giant cell arteritis: Management of two diseases of the elderly

Aging Health

Volumn 7, Issue 4, 2011, Pages 633-645

  Dejaco, Christian ^a   Duftner, Christina ^b   Dasgupta, Bhaskar ^c   Matteson, Eric L ^d   Schirmer, Michael ^e  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c SOUTHEND UNIVERSITY HOSPITAL   (United Kingdom)

^d Mayo Clinic   (United States)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

aortic aneurysm; corticosteroids; disease activity; disease modifying antirheumatic drugs; giant cell arteritis; outcome research; polymyalgia rheumatica; vasculitis

Indexed keywords

ACETYLSALICYLIC ACID; AUTOANTIBODY; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; C REACTIVE PROTEIN; CALCIUM; CORTICOSTEROID; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYCLOSPORIN; FLUORODEOXYGLUCOSE F 18; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE; PREDNISONE; RHEUMATOID FACTOR; RITUXIMAB; VITAMIN D;

ALGORITHM; BLOOD VESSEL BIOPSY; BONE DISEASE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL EXAMINATION; CLINICAL FEATURE; COMORBIDITY; CONGENITAL BLOOD VESSEL MALFORMATION; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DYSPEPSIA; DYSPHAGIA; EARLY DIAGNOSIS; ECHOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; GIANT CELL ARTERITIS; HUMAN; HYPERTENSION; LABORATORY TEST; LOW DRUG DOSE; MEDICAL RESEARCH; MEDICAL SOCIETY; MENTAL DISEASE; MONONEUROPATHY; MOOD DISORDER; MORTALITY; MYALGIA; MYOPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; POLYNEUROPATHY; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PREDICTION; PSYCHOSIS; REPEATED DRUG DOSE; REVIEW; RHEUMATIC POLYMYALGIA; SCORING SYSTEM; SECONDARY INFECTION; SENSITIVITY AND SPECIFICITY; SYMPTOM; TEMPORAL ARTERITIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VISUAL IMPAIRMENT;

EID: 80051713329     PISSN: 1745509X     EISSN: 17455103     Source Type: Journal    
DOI: 10.2217/ahe.11.50     Document Type: Review

References (129)

1. Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. Ann. Intern. Med. 139, 505-515 (2003).
2. Doran MF, Crowson CS, O'Fallon WM, Hunder GG, Gabriel SE. Trends in the incidence of polymyalgia rheumatica over a 30 year period in Olmsted county, Minnesota, USA. J. Rheumatol. 29, 1694-1697 (2002).
3. Crowson CS, Matteson EL, Myasoedova E et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthr. Rheum. 63, 633-639 (2011).
4. Bernatsky S, Joseph L, Pineau CA et al. Polymyalgia rheumatica prevalence in a population-based sample. Arthr. Rheum. 61, 1264-1267 (2009).
5. Kermani TA, Schäfer VS, Crowson CS et al. Increase in age at onset of giant cell arteritis: a population-based study. Ann. Rheum. Dis. 69, 780-781 (2010).
6. Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. N. Engl. J. Med. 349, 160-169 (2003).
7. Weyand CM, Younge BR, Goronzy JJ. T cells in arteritis and atherosclerosis. Curr. Opin. Lipidol. 19, 469-477 (2008).
8. Krupa WM, Dewan M, Jeon MS et al. Trapping of misdirected dendritic cells in the granulomatous lesions of giant cell arteritis. Am. J. Pathol. 161, 1815-1823 (2002).
9. Ma-Krupa W, Jeon MS, Spoerl S, Tedder TF, Goronzy JJ, Weyand CM. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J. Exp. Med. 199, 173-183 (2004).
10. Weyand CM, Tetzlaff N, Bjornsson J, Brack A, Younge B, Goronzy JJ. Disease patterns and tissue cytokine profiles in giant cell arteritis. Arthritis Rheum. 40, 19-26 (1997).
11. Deng J, Younge BR, Olshen RA, Goronzy JJ, Weyand CM. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation 121, 906-915 (2010).
12. Weyand CM, Ma-Krupa W, Goronzy JJ. Immunopathways in giant cell arteritis and polymyalgia rheumatica. Autoimmun. Rev. 3, 46-53 (2004).
13. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet 372, 234-245 (2008).
14. Blockmans D, De Ceuninck L, Vanderschueren S, Knockaert D, Mortelmans L, Bobbaers H. Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients. Rheumatology (Oxford) 46(4), 672-677 (2007).
15. Wagner AD, Dejaco C. Emergencies in rheumatology: giant cell arteritis with visual symptoms, vertebrobasilar insufficiency or other ischaemic complications. Aktuel. Rheumatol. 35, 43-48 (2010).
16. Dasgupta B, Borg FA, Hassan N et al. BSR and BHPR standards, guidelines and audit working group. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford) 49, 1594-1597 (2010).
17. Mukhtyar C, Guillevin L, Cid MC et al. EULAR recommendations for the management of large vessel vasculitis. Ann. Rheum. Dis. 68(3), 318-323 (2009).
18. Cimmino MA, Parodi M, Zampogna G, Barbieri F, Garlaschi G. Polymyalgia rheumatica is associated with extensor tendon tenosynovitis but not with synovitis of the hands: a magnetic resonance imaging study. Rheumatology 50, 494-499 (2011).
19. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N. Engl J. Med. 347, 261-271 (2002).
20. Nesher G, Nesher R, Rozenman Y, Sonnenblick M. Visual hallucinations in giant cell arteritis: association with visual loss. J. Rheumatol. 28, 2046-2048 (2001).
21. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Gomez-Acebo I et al. Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis. Medicine (Baltimore) 88, 227-235 (2009).
22. Schmidt WA, Seifert A, Gromnica-Ihle E, Krause A, Natusch A. Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis. Rheumatology (Oxford).47, 96-101 (2008).
23. Blockmans D, de Ceuninck L, Vanderschueren S et al. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthr. Rheum. 55, 131-137 (2006).
24. Evans JM, O'Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann. Intern. Med. 122, 502-507 (1995).
25. Gonzalez-Gay MA, Garcia-Porrua C, Pineiro A, Pego-Reigosa R, Llorca J, Hunder GG. Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population-based study. Medicine 83, 335-341 (2004).
26. García-Martínez A, Hernández-Rodríguez J, Arguis P et al. Development of aortic aneurysm/dilatation during the followup of patients with giant cell arteritis: a cross-sectional screening of fifty-four prospectively followed patients. Arthr. Rheum. 59, 422-430 (2008).
27. Schmidt WA, Moll A, Seifert A, Schicke B, Gromnica-Ihle E, Krause A. Prognosis of large-vessel giant cell arteritis. Rheumatology (Oxford) 47, 1406-1408 (2008).
28. Klein RG, Hunder GG, Stanson AW, Sheps SG. Large artery involvement in giant cell (temporal) arteritis. Ann. Intern. Med. 83, 806-812 (1975).
29. Godoy P, Araujo Sde A, Paulino E Jr, Lana-Peixoto MA. Coronary giant cell arteritis and acute myocardial infarction. Arq. Bras. Cardiol. 88, e84-e87 (2007).
30. Kalimanovska-Ostric DV, Simic-Ogrizovic SP, Bonaci-Nikolic BM, Bozic VD, Ostric VZ, Davidovic LB. Heart and renal failure in renovascular hypertension caused by giant cell arteritis-case report. Clin. Nephrol. 67, 58-60 (2007).
31. Sujobert P, Fardet L, Marie I et al. Mesenteric ischemia in giant cell arteritis: 6 cases and a systematic review. J. Rheumatol. 34(8), 1727-1732 (2007).
32. Brack A, Martinez-Taboada V, Stanson A, Goronzy JJ, Weyand CM. Disease pattern in cranial and large-vessel giant cell arteritis. Arthr. Rheum. 42, 311-317 (1999).
33. Assie C, Janvresse A, Plissonnier D, Levesque H, Marie I. Long-term follow-up of upper and lower extremity vasculitis related to giant cell arteritis: a series of 36 patients. Medicine (Baltimore) 90, 40-51 (2011).
34. Kermani TA, Warrington KJ. Lower extremity vasculitis in polymyalgia rheumatica and giant cell arteritis. Curr. Opin. Rheumatol. 23(1), 38-42 (2011).
35. Caselli RJ, Daube JR, Hunder GG, Whisnant JP. Peripheral neuropathic syndromes in giant cell (temporal) arteritis. Neurology 38, 685-689 (1988).
36. Dasgupta B, Cimmino M, Maradit-Kremers H et al. Development of classification criteria for polymyalgia rheumatica (PMR): results from an international, prospective, multi-center longitudinal study. Arthr. Rheum. 62, S689 (2010).
37. Chuang TY, Hunder GG, Ilstrup DM, Kurland LT. Polymyalgia rheumatica: a 10-year epidemiologicand clinical study. Ann. Intern. Med. 97, 672-680 (1982).
38. Healey LA. Long-term follow-up of polymyalgia rheumatica: evidence for synovitis. Semin. Arthritis Rheum. 13, 322-328 (1984).
39. Bird HA, Esselinckx W, Dixon AS, Mowat AG, Wood PH. An evaluation of criteria for polymyalgia rheumatica. Ann. Rheum. Dis. 38, 434-439 (1979).
40. Jones JG, Hazleman BL. Prognosis and management of polymyalgia rheumatica. Ann. Rheum. Dis. 40, 1-5 (1981).
41. Proven A, Gabriel SE, O'Fallon WM, Hunder GG. Polymyalgia rheumatica with low erythrocyte sedimentation rate at diagnosis. J. Rheumatol. 26, 1333-1337 (1999).
42. Helfgott SM, Kieval RI. Polymyalgia rheumatica in patients with a normal erythrocyte sedimentation rate. Arthr. Rheum. 39, 304-307 (1996).
43. Cantini F, Salvarani C, Olivieri I et al. Inflamed shoulder structures in polymyalgia rheumatica with normal erythrocyte sedimentation rate. Arthr. Rheum. 44, 1155-1159 (2001).
44. Cantini F, Salvarani C, Olivieri I et al. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin. Arthr. Rheum. 30, 17-24 (2000).
45. Dasgupta B, Hutchings A, Hollywood J, Nutter L. Autoantibodies to cyclic citrullinated peptide in a PMR inception cohort from the PMR outcomes study. Ann. Rheum. Dis. 67, 903-904 (2008).
46. Dejaco C, Klotz W, Larcher H, Duftner C, Schirmer M, Herold M. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res. Ther. 8, R119 (2006).
47. Lopez-Hoyos M, Ruiz de Alegria C, Blanco R et al. Clinical utility of anti-CCP antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and polymyalgia rheumatica. Rheumatology 43, 655-657 (2004).
48. Kawasaki A, Purvin V. Giant cell arteritis: an updated review. Acta Ophthalmol. 87, 13-32 (2009).
49. Salvarani C, Barozzi L, Cantini F et al. Cervical interspinous bursitis in active polymyalgia rheumatica. Ann. Rheum. Dis. 67, 758-761 (2008).
50. Falsetti P, Acciai C, Volpe A, Lenzi L. Ultrasonography in early assessment of elderly patients with polymyalgic symptoms: a role in predicting diagnostic outcome? Scand. J. Rheumatol. 40, 57-63 (2011).
51. Dasgupta B, Cimmino M, Maradit-Kremers H et al. Utility of ultrasound in the diagnostic assessment of patients with shoulder pain in evaluation for polymyalgia rheumatica: results from an international, prospective, multi-center longitudinal study. Arthr. Rheum. 62, S682 (2010).
52. Hunder GG, Bloch DA, Michel BA et al. The American college of rheumatology 1990 criteria for the classification of giant cell arteritis. Arthr. Rheum. 33, 1122-1128 (1990).
53. Younge BR, Cook BE Jr, Bartley GB, Hodge DO, Hunder GG. Initiation of glucocorticoid therapy: before or after temporal artery biopsy? Mayo Clin. Proc. 79, 483-491 (2004).
54. Breuer GS, Nesher R, Nesher G. Effect of biopsy length on the rate of positive temporal artery biopsies. Clin. Exp. Rheumatol. 27(1 Suppl. 52), S10-S13 (2009).
55. Boyev LR, Miller NR, Green WR. Efficacy of unilateral versus bilateral temporal artery biopsies for the diagnosis of giant cell arteritis. Am. J. Ophthalmol. 128, 211-215 (1999).
56. Ball EL, Walsh SR, Tang TY, Gohil R, Clarke JM. Role of ultrasonography in the diagnosis of temporal arteritis. Br. J. Surg. 97, 1765-1771 (2010).
57. Arida A, Kyprianou M, Kanakis M, Sfikakis PP. The diagnostic value of ultrasonography-derived edema of the temporal artery wall in giant cell arteritis: a second meta-analysis. BMC Musculoskelet. Disord. 11, 44 (2010).
58. Pipitone N, Versari A, Salvarani C. Role of imaging studies in the diagnosis and follow-up of large-vessel vasculitis: an update. Rheumatology 47, 403-408 (2008).
59. Bley TA, Uhl M, Venhoff N, Thoden J, Langer M, Markl M. 3-T MRI reveals cranial and thoracic inflammatory changes in giant cell arteritis. Clin. Rheumatol. 26, 448-450 (2007).
60. Wenger M, Gasser R, Donnemiller E et al. Images in cardiovascular medicine. Generalized large vessel arteritis visualized by 18fluorodeoxyglucose- positron emission tomography. Circulation 107(6), 923 (2003).
61. Blockmans D, Coudyzer W, Vanderschueren S et al. Relationship between fluorodeoxyglucose uptake in the large vessels and late aortic diameter in giant cell arteritis. Rheumatology (Oxford) 47(8), 1179-1184 (2008).
62. Hautzel H, Sander O, Heinzel A, Schneider M, Müller HW. Assessment of large-vessel involvement in giant cell arteritis with 18F-FDG PET: introducing an ROC-analysis-based cutoff ratio. J. Nucl. Med. 49, 1107-1113 (2008).
63. Hernández-Rodríguez J, Cid MC, López-Soto A, Espigol-Frigolé G, Bosch X. Treatment of polymyalgia rheumatica: a systematic review. Arch. Intern. Med. 169(20), 1839-1850 (2009).
64. Dasgupta B, Borg FA, Hassan N et al. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford) 49(1), 186-190 (2010).
65. Schmidt WA, Gromnica-Ihle E, Caspary L, Stiegler H. Polymyalgia rheumatica und riesenzellarteriitis (arteriitis temporalis).In: Rationelle Diagnostik und Therapie in der Inneren Medizin: Leitlinien. Dierkesmann R, Fleig WE, Heidrich H et al. (Eds).Elsevier, Urban & Fischer, Munich, Germany (2006).
66. Mackie SL, Hensor EM, Haugeberg G, Bhakta B, Pease CT. Can the prognosis of polymyalgia rheumatica be predicted at disease onset? Results from a 5-year prospective study. Rheumatology (Oxford) 49, 716-722 (2010).
67. Hutchings A, Hollywood J, Lamping DL et al. Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. Arthr. Rheum. 57(5), 803-809 (2007).
68. Dasgupta B, Dolan AL, Panayi GS, Fernandes L. An initially double-blind controlled 96-week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica. Br. J. Rheumatol. 37(2), 189-195 (1998).
69. Mazlumzadeh M, Hunder GG, Easley KA et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthr. Rheum. 54, 3310-3318 (2006).
70. Spies CM, Burmester GR, Buttgereit F. Methotrexate treatment in large vessel vasculitis and polymyalgia rheumatica. Clin. Exp. Rheumatol. 28(5 Suppl. 61), S172-S177 (2010).
71. Mahr AD, Jover JA, Spiera RF et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthr. Rheum. 56, 2789-2797 (2007).
72. De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann. Rheum. Dis. 45, 136-138 (1986).
73. Schaufelberger C, Andersson R, Nordborg E. No additive effect of cyclosporin A compared with glucocorticoid treatment alone in giant cell arteritis: results of an open, controlled, randomized study. Br. J. Rheumatol. 37, 464-465 (1998).
74. Schaufelberger C, Möllby H, Uddhammar A, Bratt J, Nordborg E. No additional steroid-sparing effect of cyclosporine A in giant cell arteritis. Scand. J. Rheumatol. 35, 327-329 (2006).
75. Sailler L, Lapeyre-Mestre M, Geffray L et al. Adding hydroxychloroquine to prednisone does not improve the outcome in giant cell arteritis. A double blind randomized controlled trial. Arthr. Rheum. 61, S1972 (2009).
76. Hoffman GS, Cid MC, Rendt-Zagar KE et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis. Ann. Intern. Med. 146, 621-630 (2007).
77. Salvarani C, Macchioni P, Manzini C et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann. Intern. Med. 146(9), 631-639 (2007).
78. Kreiner F, Galbo H. Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial. Arthr. Res. Ther. 12, R176 (2010).
79. Catanoso MG, Macchioni P, Boiardi L, Pipitone N, Salvarani C. Treatment of refractory polymyalgia rheumatica with etanercept: an open pilot study. Arthr. Rheum. 57(8), 1514-1519 (2007).
80. Martínez-Taboada VM, Rodríguez-Valverde V, Carreño L et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann. Rheum. Dis. 67(5), 625-630 (2008).
81. Mayrbaeurl B, Hinterreiter M, Burgstaller S, Windpessl M, Thaler J. The first case of a patient with neutropenia and giant-cell arteritis treated with rituximab. Clin. Rheumatol. 26(9), 1597-1598 (2007).
82. Bhatia A, Ell PJ, Edwards JC. Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann. Rheum. Dis. 64(7), 1099-1100 (2005).
83. Berger CT, Wolbers M, Meyer P, Daikeler T, Hess C. High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition. Rheumatology 48, 258-261 (2009).
84. Narváez J, Bernad B, Gómez-Vaquero C et al. Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis. Clin. Exp. Rheumatol. 26(3 Suppl. 49), S57-S62 (2008).
85. Lee MS, Smith SD, Galor A, Hoffman GS. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthr. Rheum. 54, 3306-3309 (2006).
86. Nesher G, Berkun Y, Mates M, Baras M, Rubinow A, Sonnenblick M. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthr. Rheum. 50, 1332-1337 (2004).
87. Duftner C, Dejaco C, Schirmer M. Polymyalgia rheumatica. Internist 50, 51-57 (2009).
88. Cimmino MA, Salvarani C, Macchioni P et al. Long-term follow-up of polymyalgia rheumatica patients treated with methotrexate and steroids. Clin. Exp. Rheumatol. 26, 395-400 (2008).
89. Narváez J, Nolla-Solé JM, Clavaguera MT, Valverde-García J, Roig-Escofet D. Longterm therapy in polymyalgia rheumatica: effect of coexistent temporal arteritis. J. Rheumatol. 26(9), 1945-1952 (1999).
90. Pountain G, Hazleman B. Erythrocyte sedimentation rate (ESR) at presentation is a prognostic indicator for duration of treatment in polymyalgia rheumatica (PMR) Br. J. Rheumatol. 36(4), 508-509 (1997).
91. Dolan AL, Moniz C, Dasgupta B et al. Effects of inflammation and treatment on bone turnover and bone mass in polymyalgia rheumatica. Arthr. Rheum. 40(11), 2022-2029 (1997).
92. Pulsatelli L, Boiardi L, Pignotti E et al. Serum interleukin-6 receptor in polymyalgia rheumatica: a potential marker of relapse/recurrence risk. Arthr. Rheum. 59(8), 1147-1154 (2008).
93. Salvarani C, Cantini F, Niccoli L et al. Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study. Arthr. Rheum. 53, 33-38 (2005).
94. Schreiber S, Buyse M. The CRP initial response to treatment as prognostic factor in patients with polymyalgia rheumatica. Clin. Rheumatol. 14(3), 315-318 (1995).
95. Weyand CM, Fulbright JW, Evans JM, Hunder GG, Goronzy JJ. Corticosteroid requirements in polymyalgia rheumatica. Arch. Intern. Med. 159(6), 577-584 (1999).
96. Dejaco C, Wipfler-Freißmuth E, Duftner C, Schirmer M. Assessment of disease activity of systemic vasculitides in clinical practice. Aktuel. Rheumatol. 34, 180-185 (2009).
97. Borg FA, Dasgupta B. Treatment and outcomes of large vessel arteritis. Best. Prac. Res. Clin. Rheumatol. 23, 325-337 (2009).
98. Makkuni D, Bharadwaj A, Wolfe K et al. Is intimal hyperplasia a marker of neuro-ophthalmic complications of giant cell arteritis? Rheumatology 47, 488-490 (2008).
99. Chatelain D, Duhaut P, Schmidt J et al. Pathological features of temporal arteries in patients with giant cell arteritis presenting with permanent visual loss. Ann. Rheum. Dis. 68, 84-88 (2009).
100. Salvarani C, Cimino L, Macchioni P et al. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthr. Rheum. 53, 293-297 (2005).
101. Loddenkemper T, Pankaj P, Katzan I, Plant GT. Risk factors for early visual deterioration in temporal arteritis. J. Neurol. Neurosurg. Psych. 78, 1255-1259 (2007).
102. Nesher G, Berkun Y, Mates M et al. Risk factors for cranial ischemic complications in giant cell arteritis. Medicine 83, 114-122 (2004).
103. Gonzalez-Gay MA, Garcia-Porrua C, Llorca J et al. Visual manifestations of giant cell arteritis: trends and clinical spectrum in 161 patients. Medicine 79, 283-292 (2000).
104. Schmidt WA, Krause A, Schicke B, Kuchenbecker J, Gromnica-Ihle E. Do temporal artery duplex ultrasound findings correlate with ophthalmic complications in giant cell arteritis? Rheumatology 48, 383-385 (2009).
105. Dejaco C, Duftner C, Cimmino MA et al. Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus. Ann. Rheum. Dis. 70, 447-453 (2011).
106. Salvarani C, Cantini F, Boiardi L, Hunder GG. Laboratory investigations useful in giant cell arteritis and Takayasu's arteritis. Clin. Exp. Rheumatol. 21(Suppl. 32), S23-S28 (2003).
107. Macchioni P, Catanoso MG, Pipitone N, Boiardi L, Salvarani C. Longitudinal examination with shoulder ultrasound of patients with polymyalgia rheumatica. Rheumatology 48, 1566-1569 (2009).
108. Jiménez-Palop M, Naredo E, Humbrado L et al. Ultrasonographic monitoring of response to therapy in polymyalgia rheumatica. Ann. Rheum. Dis. 69, 879-882 (2010).
109. Aschwanden M, Kesten F, Stern M et al. Vascular involvement in patients with giant cell arteritis determined by duplex sonography of 2 × 11 arterial regions. Ann. Rheum. Dis. 69, 1356-1359 (2010).
110. Bley TA, Markl M, Schelp M et al. Mural inflammatory hyperenhancement in MRI of giant cell (temporal) arteritis resolves under corticosteroid treatment. Rheumatology 47, 65-67 (2008).
111. Ray JG, Mamdani MM, Geerts WH. Giant cell arteritis and cardiovascular disease in older adults. Heart 91, 324-328 (2005).
112. Le Page L, Duhaut P, Seydoux D et al. Incidence of cardiovascular events in giant cell arteritis: preliminary results of a prospective double cohort study (GRACG).Rev. Med. Interne. 27, 98-105 (2006).
113. Borg FA, Dasgupta B. Peripheral arterial disease in polymyalgia rheumatica. Arthr. Res. Ther. 11, 111 (2009).
114. Ji J, Liu X, Sundquist K, Sundquist J, Hemminki K. Cancer risk in patients hospitalized with polymyalgia rheumatica and giant cell arteritis: a follow-up study in Sweden. Rheumatology 49, 1158-1163 (2010).
115. Anderson LA, Pfeiffer RM, Landgren O, Gadalla S, Berndt SI, Engels EA. Risks of myeloid malignancies in patients with autoimmune conditions. Br. J. Cancer 100, 822-828 (2009).
116. Hill CL, Cole A, Rischmueller M et al. Risk of cancer in patients with biopsy-proven giant cell arteritis. Rheumatology 49, 756-759 (2010).
117. Kermani TA, Schäfer VS, Crowson CS et al. Malignancy risk in patients with giant cell arteritis: a population-based cohort study. Arthr. Care. Res. 62, 149-154 (2010).
118. Gonzalez-Gay MA, Lopez-Diaz MJ, Martinez-Lado L et al. Cancer in biopsy-proven giant cell arteritis. A population-based study. Semin. Arthr. Rheum. 37, 156-163 (2007).
119. Proven A, Gabriel SE, Orces C, O'Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and treatment outcomes. Arthr. Rheum. 49, 703-708 (2003).
120. Gabriel SE, Sunku J, Salvarani C, O'Fallon WM, Hunder GG. Adverse outcomes of anti-inflammatory therapy among patients with polymyalgia rheumatica. Arthr. Rheum. 40, 1873-1878 (1997).
121. Gonzalez-Gay MA, Garcia-Porrua C, Vazquez-Caruncho M, Dababneh A, Hajeer A, Ollier WE. The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study. J. Rheumatol. 26, 1326-1332 (1999).
122. Hoes JN, Jacobs JW, Verstappen SM, Bijlsma JW, Van der Heijden GJ. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann. Rheum. Dis. 68, 1833-1838 (2009).
123. Crow RW, Katz BJ, Warner JE et al. Giant cell arteritis and mortality. J. Gerontol. A Biol. Sci. Med. Sci. 64, 365-369 (2009).
124. Pipitone N, Boiardi L, Bajocchi G, Salvarani C. Long-term outcome of giant cell arteritis. Clin. Exp. Rheumatol. 24(2 Suppl. 41), S65-S70 (2006).
125. Luqmani RA, Suppiah R, Grayson PC, Merkel PA, Watts R. Nomenclature and classification of vasculitis-update on the ACR/EULAR diagnosis and classification of vasculitis study (DCVAS).Clin. Exp. Immunol. 164(Suppl. 1), 11-13 (2011).
126. Spies CM, Cutolo M, Straub RH, Burmester GR, Buttgereit F. More night than day-circadian rhythms in polymyalgia rheumatica and ankylosing spondylitis. J. Rheumatol. 37, 894-899 (2010).
127. Hagihara K, Kawase I, Tanaka T, Kishimoto T. Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica. J. Rheumatol. 37, 1075-1076 (2010).
128. Seitz M, Reichenbach S, Bonel HM, Adler S, Wermelinger F, Villiger PM. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. Swiss. Med. Wkly 141, w13156 (2011).
129. Piggott K, Deng J, Warrington K et al. Blocking the NOTCH pathway inhibits vascular inflammation in large-vessel vasculitis. Circulation 123, 309-318 (2011).